• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

    5/28/25 7:00:00 AM ET
    $GSK
    $SPRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    • If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs)
    • An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs2
    • Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846).3 The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial. 

    The trial met the primary endpoint of non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin in hospitalized adult patients with cUTI, including pyelonephritis, on overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The IDMC review did not identify any new safety concerns beyond what has been reported in other studies with tebipenem, with diarrhea and headache as the two most reported adverse events. GSK plans to work with US regulatory authorities to include the data as part of a filing in 2H 2025. Full results will be submitted for presentation at an upcoming scientific congress and for publication in a peer-reviewed journal.

    Esther Rajavelu, Chief Executive Officer, Spero, said: "Achieving the primary endpoint in the PIVOT-PO trial marks a significant milestone for tebipenem HBr. If approved, we believe tebipenem HBr is well positioned to change the treatment landscape for patients diagnosed with cUTI, including pyelonephritis. We look forward to working with GSK on next steps for this program, and would like to thank the patients, site investigators and other clinical staff, and Spero employees who worked diligently to help bring the product to this advanced stage."

    An estimated 2.9 million cases of cUTIs are treated annually in the US alone.1 These infections are often caused by multi-drug-resistant pathogens and carry increased risk of morbidity and mortality.4,7 Current standard of care includes carbapenem antibiotics, especially in case of sepsis and allergies or resistance to other antibiotics, but they are only available for IV administration. This results in significant emergency department visits and hospitalizations.4,5,6

    Tony Wood, Chief Scientific Officer, GSK, added: "Complicated UTIs can have a profound impact on patients and carry a high risk of clinical complications, including sepsis and septic shock.6,7,8 Currently many need hospital-based intravenous treatment due to limited oral options for drug-resistant infections, contributing to over $6 billion per year in US healthcare costs2. These positive results add to our growing anti-infectives portfolio and reinforce the potential of tebipenem HBr as an effective oral alternative taken at home."

    The development of tebipenem HBr is supported in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800015C.

    About tebipenem HBr 

    Tebipenem pivoxil hydrobromide (HBr) is a late-stage development asset developed in collaboration with GSK. Tebipenem HBr is being developed to treat cUTIs, including pyelonephritis.

    In September 2022, Spero entered into an exclusive license agreement with GSK for the development and commercialization of tebipenem HBr in all markets, except certain Asian territories. Under this agreement GSK has sub-licensed back to Spero Therapeutics the rights and responsibility to conduct certain development work including the PIVOT-PO Phase 3 trial, after which sponsorship of the new drug application (NDA) will be transferred to GSK from Spero Therapeutics. Tebipenem HBr has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA. 

    About PIVOT-PO

    PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr versus IV imipenem cilastatin, in hospitalized adult patients with cUTI including pyelonephritis. Patients were randomized 1:1 to receive tebipenem HBr (600 mg) orally every six hours, or imipenem cilastatin (500 mg) IV every six hours, for a total of seven to ten days. The primary efficacy endpoint is overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The primary analysis for the trial is an assessment of non-inferiority (NI) in the microbiological intention-to-treat population, based on a 10% NI margin. The trial enrolled a total of 1690 patients, with randomization stratified by age, baseline diagnosis (cUTI including pyelonephritis), and the presence or absence of urinary tract instrumentation. For further details on the trial, refer to clinicaltrials.gov identifier NCT06059846.

    About complicated urinary tract infections (cUTIs) 

    cUTIs are broadly described as any UTI that carries an increased risk of morbidity and mortality.4 Definitions of cUTIs are not currently uniform among international societies and regulatory agencies.9 cUTIs encompass a heterogeneous patient population due to the wide range of host factors, comorbidities and urological abnormalities associated with cUTIs.4,9 Risk factors for cUTI include indwelling catheters, ureteric stents, neurogenic bladder, obstructive uropathy, urinary retention, urinary diversion, kidney stones, diabetes mellitus, immune deficiency, urinary tract modification, and UTIs in renal transplant patients.10

    About GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

    About Spero Therapeutics

    Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing, progress and results of Spero's Phase 3 PIVOT-PO trial; the planned NDA filing for tebipenem HBr and the timing thereof; the potential of tebipenem HBr to be the first oral carbapenem antibiotic for US patients with cUTI, including pyelonephritis; the potential benefits of any of Spero's current or future product candidates in treating patients. In some cases, forward-looking statements may be identified by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intent," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including whether tebipenem HBr will advance through the clinical development process, or at all, taking into account the effects of possible regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, clinical trial design and clinical outcomes; whether the results of such trials will warrant submission for approval from the FDA or equivalent foreign regulatory agencies; whether the FDA will ultimately approve tebipenem HBr and, if so, the timing of any such approval; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero's reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved, including, in the case of tebipenem HBr, Spero's reliance on GSK pursuant to the Exclusive License Agreement to develop tebipenem HBr and GSK's right thereunder to determine, in its sole discretion, whether to continue the PIVOT-PO trial or otherwise further develop tebipenem HBr; Spero's need for additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.

    Spero Investor Relations Contact:

    Shai Biran, PhD

    Spero Therapeutics

    [email protected]



    Spero Media Inquiries:

    [email protected]

    References

    1. Carreno JJ, et al. Longitudinal, Nationwide, Cohort Study to Assess Incidence, Outcomes, and Costs Associated With Complicated Urinary Tract Infection. Open Forum Infect Dis. 2019;6:ofz446.
    2. Lodise TP, et al. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021;49(12):1528-1534.
    3. GSK press release, 3 November 2022 – available at: https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-trials-for-gepotidacin/
    4. Sabih A, Leslie SW. Complicated urinary tract infections. StatPearls. 2023. StatPearls Publishing: Treasure Island, FL, USA.
    5. Zilberberg MD, et al. Descriptive Epidemiology and Outcomes of Hospitalisations With Complicated Urinary Tract Infections in the United States, 2018. Open Forum Infect Dis. 2022;9:ofab591.
    6. Li HK, et al. An Unsupported Preference for Intravenous Antibiotics. PLoS Med. 2015;12:e1001825.
    7. Vallejo-Torres L, et al. Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multi-drug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study. BMJ Open. 2018;8:e020251.
    8. Lodise TP, et al. Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs Among Adult Patients With Complicated Urinary Tract Infections. Open Forum Infect Dis. 2022;9:ofac307.
    9. Marantidis J, Sussman RD. Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways. Infect Drug Resist. 2023:16:1391-1405.
    10. Gomila A, et al. Predictive factors for multi-drug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrob Resist Infect Control. 2018;7:111.


    Primary Logo

    Get the next $GSK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GSK
    $SPRO

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    6/3/2025Buy → Hold
    Berenberg
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    Spero Therapeutics Inc.
    $SPRO
    12/20/2024$5.00Outperform → In-line
    Evercore ISI
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    More analyst ratings

    $GSK
    $SPRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mahadevia Ankit was granted 20,000 shares, increasing direct ownership by 3% to 709,866 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:32:05 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deshpande Milind was granted 20,000 shares, increasing direct ownership by 28% to 91,454 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:30:52 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jackson Scott Thomas was granted 20,000 shares, increasing direct ownership by 36% to 75,000 units (SEC Form 4)

      4 - Spero Therapeutics, Inc. (0001701108) (Issuer)

      6/16/25 8:29:35 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $SPRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GSK begins shipping influenza vaccine doses for the 2025-26 flu season

       GSK supports seasonal flu immunization in the US by shipping FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine) in advance of flu season GSK plc (LSE/NYSE:GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccinatio

      7/10/25 9:13:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

      With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option

      6/24/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

      Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 GSK plc (LSE/NYSE:GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays

      6/16/25 9:33:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $SPRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • GlaxoSmithKline downgraded by Berenberg

      Berenberg downgraded GlaxoSmithKline from Buy to Hold

      6/3/25 7:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $SPRO
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/10/25 6:21:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/9/25 6:20:55 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/8/25 6:28:40 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $SPRO
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since No

      4/28/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $GSK
    $SPRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spero Therapeutics Inc.

      SC 13G/A - Spero Therapeutics, Inc. (0001701108) (Subject)

      11/14/24 5:37:55 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Spero Therapeutics Inc.

      SC 13G - Spero Therapeutics, Inc. (0001701108) (Subject)

      2/14/24 4:25:21 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GSK
    $SPRO
    Financials

    Live finance-specific insights

    See more
    • Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2025 financial results and provide a business update on Tuesday, May 13, after the market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infect

      5/5/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

      Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review and reprioritization of the Company's pipeline in Q1 2025 Existing cash, together with earned development milestones from GSK, provide runway to fund operating expenses and capital expenditures into

      3/27/25 4:01:00 PM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

      CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.   To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this li

      3/18/25 8:00:00 AM ET
      $SPRO
      Biotechnology: Pharmaceutical Preparations
      Health Care